Improving Outcomes in Patients with Psoriasis and Psoriatic Arthritis - A Self-assessment Program
Dermatology
Curriculum:
Improving Outcomes in Psoriasis and Psoriatic Arthritis
Improving Outcomes in Psoriasis and Psoriatic Arthritis
Credits:
0.75 AMA PRA Category 1 Credit(s) ™
0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
May 07, 2015
May 07, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Dermatologists, rheumatologists, primary care physicians, physician assistants (PAs), nurse practitioners (NPs), registered nurses (RNs) and other clinicians managing patients with psoriasis and/or psoriatic arthritis
Relevant Terms:
Psoriasis, psoriatic arthritis
Philip J. Mease, MD
Philip J. Mease, MD
Chief of Rheumatology Research
Swedish Medical Center
Clinical Professor of Medicine
University of Washington
Seattle, WA
Bio
Philip Mease, MD, is Clinical Professor at the University of Washington School of Medicine in Seattle, Director of the Rheumatology Clinical Research Division of Swedish Medical Center, and his clinical practice is based at Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis and lupus. He conducts research in disease state metrics and is the Co-Chair of three working groups of OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia and single joint assessment, as well as being a member of the Soluble Biomarker working group. He is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group).
Dr. Mease received his undergraduate and medical degrees from Stanford University Medical School. He completed his residency in internal medicine at the University of Washington School of Medicine, where he also served as chief resident and fellow in rheumatology. He is the author of over 140 journal articles and 13 book chapters in texts including Biologics in General Medicine (Springer-Verlag, 2007), Update in Targeted Therapies in Rheumatology (Lippincott, 2007), and Rheumatology (in press). He has been the recipient of the Medical Communicator Award of the American College of Rheumatology.
Daniel Furst, MD
Daniel Furst, MD
Carl Pearson Professor of Medicine
Department of Medicine, Division of Rheumatology
Director, Rheumatology Clinical Research Center
David Geffen School of Medicine at the University of California
Los Angeles, CA
Bio
Dr. Furst is the first Carl M Pearson Professor in Rheumatology. He has been on a number of national committees concerned with rheumatic therapeutics, including as a member and Fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the FDA. He currently serves as Chairman of the Innovative Therapies Meeting of the American College of Rheumatology and Clinical Abstracts Selection Chair for the National American College of Rheumatology meeting and Chairman of the Standing Committee on Clinical Trials for the International League Against Rheumatism.
He has served or is serving on the editorial boards of Inpharma, Clinical Drug Investigation, Drugs, The Journal of Clinical Rheumatology, and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, The New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy, Annals of the Rheumatic Diseases, and The Journal of Rheumatology. Dr. Furst has published more than 400 articles and 12 books, including more than 180 research articles and more than 210 reviews or chapters in addition to two editions of a book on scleroderma. Dr. Furst's areas of research interest include RA, scleroderma and polymyosistis/dermatomyositis.
Alan Menter, MD
Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas, Southwestern Medical School
Dallas, TX
Bio
Dr. Menter has a long-held interest in psoriasis and psoriatic disease research. He co-authored the first gene discovery for psoriasis, published in Science in 1994. His research on psoriasis has examined everything from ultraviolet phototherapy, biologic therapy to the mapping of genetic patterns to predict if a person is at risk of developing psoriasis.
In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,600 patients on systemic and biologic therapy and phototherapy.
In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,600 patients on systemic and biologic therapy and phototherapy.
| 1. | Diagnose PsA in patients with established psoriasis | 2. | Determine the severity of skin and joint symptoms in patients diagnosed with psoriasis and PsA |
| 3. | Assess the benefits and risks of available therapies for individual patients with mild to moderate psoriasis and PsA | 4. | Assess the benefits and risks of available therapies for individual patients with moderate to severe psoriasis and PsA |
| 1. | Diagnose PsA in patients with established psoriasis |
| 2. | Determine the severity of skin and joint symptoms in patients diagnosed with psoriasis and PsA |
| 3. | Assess the benefits and risks of available therapies for individual patients with mild to moderate psoriasis and PsA |
| 4. | Assess the benefits and risks of available therapies for individual patients with moderate to severe psoriasis and PsA |
This activity is supported by independent educational grants from Celgene Corporation and AbbVie.
CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 75% or better on the post-test.
The online activity will take approximately 45 minutes to complete.
DISCLOSURES
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational activities. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and the credit providers have a process in place to resolve any conflict of interest.
The University of Chicago Pritzker School of Medicine staff involved in the development and review of this activity have nothing to disclose.
Joshua Kilbridge, Medical Writer, has nothing to disclose.
Kathleen Hines, MCM Education Editorial Director, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
DISCLAIMER
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago Pritzker School of Medicine, Celgene, or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 75% or better on the post-test.
The online activity will take approximately 45 minutes to complete.
DISCLOSURES
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational activities. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and the credit providers have a process in place to resolve any conflict of interest.
Philip Mease, MD, discloses the following:
Grant/Research Support: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Consultant: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Speakers' Bureau: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals
Grant/Research Support: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Consultant: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, F. Hoffman La Roche Ltd, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals; Speakers' Bureau: Abbott Laboratories, Amgen Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, Genentech Inc, Pfizer Inc, UCB Inc, Wyeth Pharmaceuticals
Daniel Furst, MD, discloses the following:
Consultant: Abbott, Actelion, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, CORRONNA, Genentech, Gilead, GlaxoSmithKline, National Institutes of Health, Novartis, Pfizer, Roche, UCB
Consultant: Abbott, Actelion, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, CORRONNA, Genentech, Gilead, GlaxoSmithKline, National Institutes of Health, Novartis, Pfizer, Roche, UCB
Alan Menter, MD discloses the following:
Advisory Board: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, Inc., LEO Pharma, Pfizer; Consultant: AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth, XenoPort; Investigator: AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix, Wyeth; Speaker: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma, Wyeth
Advisory Board: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, Inc., LEO Pharma, Pfizer; Consultant: AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth, XenoPort; Investigator: AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix, Wyeth; Speaker: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma, Wyeth
The University of Chicago Pritzker School of Medicine staff involved in the development and review of this activity have nothing to disclose.
Joshua Kilbridge, Medical Writer, has nothing to disclose.
Kathleen Hines, MCM Education Editorial Director, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
DISCLAIMER
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago Pritzker School of Medicine, Celgene, or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. |
